Literature DB >> 34992392

Distribution and Antibiotic Susceptibility Pattern of Multidrug-Resistant Bacteria and Risk Factors Among Kidney Transplantation Recipients with Infections Over 13 Years: A Retrospective Study.

Liying Gong1, Luwei Zhang2, Xiaoli Liu3, Bekzod Odilov4, Shengnan Li1, Zhao Hu1, Xiaoyan Xiao1.   

Abstract

BACKGROUND: Infection ranks as the most common complication after kidney transplantation (KT) and threatens outcomes of kidney transplantation recipients (KTR). This study aimed to investigate the microbiological profile of infection, assess bacterial resistance and identify risk factors for multidrug-resistant (MDR) bacterial infection among KTR.
METHODS: During the study period, 866 recipients underwent kidney transplant surgery. We studied the distribution of pathogens, resistance rate of MDR bacteria and the risk factors of MDR bacterial infection.
RESULTS: Totally, 214 species of pathogens (110 species were MDR bacteria) were isolated in 119 KTR. Escherichia coli (E. coli) was the most common bacteria of the infection. MDR extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) were most resistant to ampicillin, cefazolin, ciprofloxacin and complex sulfamethoxazole, while quite sensitive to imipenem, amikacin and piperacillin/tazobactam (PIT). All MDR gram-positive bacteria were quite sensitive to linezolid and vancomycin, except that MDR Staphylococcus was also susceptible to rifampicin. Female gender (OR = 3.497, 95% CI = 1.445-8.467, P = 0.006), pathogen types > 1 (OR = 3.832, 95% CI = 1.429-10.273, P = 0.008) and postoperative time < 3 months (OR = 0.331, 95% CI = 0.137-0.799, P = 0.014) were independent risk factors for MDR bacterial infection.
CONCLUSION: PIT and amikacin may be an alternative choice of ESBL-E infection. Rifampicin can also be prescribed for MDR Staphylococcus infection. MDR bacterial infection was associated with female gender, pathogen types more than 1 and 3 months postoperative period.
© 2021 Gong et al.

Entities:  

Keywords:  ESBL; KT; MDR; kidney transplantation; multidrug-resistant; piperacillin/tazobactam; risk factor

Year:  2021        PMID: 34992392      PMCID: PMC8713706          DOI: 10.2147/IDR.S318941

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


Introduction

Kidney transplantation (KT), as the only curable option of treatment for chronic kidney disease, is threatened by all kinds of infections since they can pose a risk of acute rejection, delayed graft function, endanger allograft and patients’ survival, and result in longer hospital duration.1–4 Moreover, they accounts for approximately 18% to 23% of death after KT.5 The vast majority of infections occur within 6 months after surgery, especially within the first month. The incidence rate of infections following renal transplantation tends to follow a predictable temporal pattern that depends on the intensity of immunosuppression, female gender, advanced age and various implants to a large extent.6 During this interval, urinary tract infection (UTI) is the most prevalent infections with Escherichia coli (E. coli) being the predominant bacteria.6 In recent decades, the incidence of infection caused by multidrug-resistant (MDR) bacteria including extended spectrum β-lactamase (ESBL)-producing bacteria has been increasing worldwide. It has also become a global health priority since its several limitations including less treatment experience, higher incidence of adverse effects and limited therapeutic options are still present.7,8 The use of broad-spectrum antibiotics, antibiotic abuse and more potent immunosuppressive regimens as well as other risk factors may contribute to the increase.1,9 KTR are highly vulnerable to the threat of MDR bacterial infections and face a three times higher recurrence risk compared to those infected with non-MDR infection.10,11 Thus, in order to improve the quality life of KTR and curtails the development of MDR bacteria, the surveillance of infection is very critical especially for MDR bacterial infection. This study was conducted to investigate the microbiologic profile of bacteria, to assess the drug resistance of MDR bacteria, and verify the risk factors of MDR bacterial infection.

Materials and Methods

Study Design and Patients

This retrospective study was performed based on reviewing medical records of KTR in Qilu hospital of Shandong university, Jinan, China from January 1, 2007 to December 31, 2019. ALL recipients received anti-thymocyte globulin (ATG) or anti-interleukin-2 receptor antibodies as an induction therapy. All KTR who diagnosed as infection with positive specimens were included in the study. All the following information was gathered for each patient: the date of infection, site of the infection, specimen type, pathogen, clinical characteristics, sensitivity to antibiotics and laboratory findings. Duplicate strains from the same site during hospitalization of the same patient, patients with absence of drug sensitivity test, contaminated specimens and negative cultures were excluded. All source of the donated organs were from living relative donor, cadaveric kidneys or donation after cardiac death donors with written informed consent, which was conducted in accordance with the Declaration of Istanbul. The study was approved by Medical Ethics Committee for clinical Studies of Qilu Hospital of Shandong University in adherence to the Declaration of Helsinki. Patient consent to review their medical records was required by the ethics committee.

Microbiologic Analysis

Antimicrobial susceptibility was determined by the Kirby-Bauer disk diffusion method, and the minimum inhibitory concentration was tested by agar dilution. Determining whether the bacteria was resistant, intermediate or sensitive was according to Clinical and Laboratory Standards Institute. In this study intermediate susceptibility was considered as resistant.

Statistical Analysis

Data were analyzed by IBM SPSS statistics version 22.0 software (IBM SPSS, Armonk, NY, USA). Categorical variables were compared by Pearson’s χ2 test or Fisher’s exact test when appropriate. Continuous variables were presented as mean ± SD. We use logistic regression to analyze univariate and multivariate analysis. Variables with a P-value < 0.05 in the univariate analysis were introduced into the subsequent multivariate analysis based on enter logistic regression. Associations were displayed as odds ratios (OR) with a 95% CI. All P values < 0.05 were considered as statistically significant.

Results

Basic Characteristics of KTR with Infection

There were 866 patients undergone KT surgery during the study period. Totally, 119 patients (40 females and 79 males, mean age 39.5 ± 12.3 years) were diagnosed with 142 episodes of culture-proven infection and a total of 214 species of pathogens were isolated. Primary glomerulonephritis was the most common cause of end-stage renal disease leading to transplantation. More than 70% recipients received tacrolimus as main immune maintenance therapy. During the study period, 8 recipients died during hospitalization and 7 recipients’ deaths were caused by infection with 5 deaths of MDR bacterial infection. The basic characteristics of the recipients were shown in Table 1.
Table 1

The Clinical Characteristics of Patients with Culture-Proven Infections

VariablesValue
Female40 (33.6%)
Age39.5±12.3 (range: 9–66)
Donor type, live36 (30.3%)
Etiology of kidney disease
 Primary glomerulonephritis113 (95.0%)
 Diabetic Nephropathy5 (4.2%)
 Polycystic kidney disease1 (0.8%)
Comorbidities
 Hypertension89 (74.8%)
 Diabetes12 (10.1%)
Immunosuppression maintenance
 FK506 + MM + P89 (74.8%)
 CSA + MM + P30 (25.2%)
Temperature > 38.5°C45 (35.4%)
Length of hospitalization31.5 ± 2.0 (rang: 4–96)
Laboratory findings
 Creatinine > 1.5mg/l59 (46.7%)
 Albumin < 30g/l42 (33.1%)
 RDW > 1741 (32.8%)
Specimens source
 Urine103 (48.1%)
 Sputum65 (30.4%)
 Blood12 (5.6%)
 Others34 (15.9%)

Abbreviations: FK506, tacrolimus; MM, mycophenolate mofetil; P, prednisone; RDW, red blood cell distribution width.

The Clinical Characteristics of Patients with Culture-Proven Infections Abbreviations: FK506, tacrolimus; MM, mycophenolate mofetil; P, prednisone; RDW, red blood cell distribution width.

Distribution of Pathogens and Infection Types by Time Course

Among the 214 species of pathogens, 193 were bacteria (146 were gram-negative bacteria and 47 were gram-positive bacteria) and 21 were fungus (Table 2). The top 3 pathogens were E. coli, Pseudomonas aeruginosa (P. aeruginosa) and Enterococcus Faecium (E. Faecium). Among the gram-negative bacteria, 72 species were from Enterobacteriaceae family with 52 species of MDR bacteria and 65 species from non-fermentative bacteria with 19 species of MDR bacteria, respectively. Compared with Staphylococcus, genus of Enterococcus was more common, especially E. Faecium. KTR were also in the risk of fungus infection. Candida glabrata and Candida tropicalis were the most common fungus. Although the incidence of MDR bacteria fluctuated by time course, in overall, a clear upward trend could be observed in subjects. The overall MDR bacteria detection rate among the three intervals represented a significant difference (P = 0.02) and was mainly caused by the gram-negative bacteria.
Table 2

Distribution of Micrograms and Changes in the Incidence Rate of MDR Bacteria Types by Year (MDR Number/Total Number)

Microgram2007–20102011–20142015–2019TotalP-value
Gram-negative bacteria13/3827/5433/5473/1460.04*
 Enterobacteriaceae10/1816/2226/3252/720.015
 Non-fermentative2/1911/276/1919/650.082
 Others1/10/51/32/9/
Gram-positive bacteria7/1015/2015/1737/47/
 Enterococcus4/69/138/921/28/
 Staphylococcus3/46/67/816/18/
 Others0/01/00/00/1/
Fungus†551121/
Total bacteria20/4842/7448/71110/1930.02*

Notes: †For fungus, the table only showed the total number. *The P-values are statistically significant.

Abbreviation: MDR, multi-drug resistant;

Distribution of Micrograms and Changes in the Incidence Rate of MDR Bacteria Types by Year (MDR Number/Total Number) Notes: †For fungus, the table only showed the total number. *The P-values are statistically significant. Abbreviation: MDR, multi-drug resistant; We studied the distribution of pathogens in 3 different aspects depending on postoperative time, infection type and source of specimens. In 4 different intervals (postoperative 3 months, within the 3 to 6 months, within the 6 months to 1 year and after the 1 year postoperatively), the majority of pathogens were isolated within the 3 months postoperatively. P. aeruginosa was the most identified pathogen during the initial postsurgical 3 months followed by E. coli, fungus and E. Faecium. After the initial postoperative 3 months, E. coli became the most common pathogen, especially 1 year postoperatively (Figure 1A).
Figure 1

(A) Time course of infection by the causative pathogens. E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; K. pneumoniae: Klebsiella pneumoniae; E. faecium: Enterococcus faecium. (B) Time course and frequency of infections post transplantation (m).

(A) Time course of infection by the causative pathogens. E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; K. pneumoniae: Klebsiella pneumoniae; E. faecium: Enterococcus faecium. (B) Time course and frequency of infections post transplantation (m). As depicted in Figure 1B, the onset of various infections was concentrated in the first 3 months after surgery, especially in the first month. In our study, 94 (66.2%) episodes of infection occurred within 3 months postoperatively, of which 72 (50.1%) were found in initial month. UTI was the most common infection complication after KT surgery in all intervals. P. aeruginosa and E. coli were the most frequent isolated bacteria within the postoperative 3 months and after the 1 year postoperatively, respectively. For pneumonia, non-fermentative bacteria comprised the majority of pathogens, P. aeruginosa in particular. Among bloodstream infection (BSI), gram-negative bacteria were in abundance with E. coli being the most common bacteria. Interestingly, nearly all of BSI were unknown for primary source (81.8%). Gram-positive bacteria were most frequent bacteria among surgical wound infection (SWI). Other types of infection mainly included abdominal wall abscess, graft perirenal abscess and peritonitis. Most of the pathogens were MDR bacteria. Among the sources of pathogens, 103 species were from urine, 65 species were from sputum, 12 species from blood, and 34 species from other specimens including secretions, venous catheter tip respectively. E. coli was the most common detected bacteria in urine sample, blood and others (secretions) sample, while P. aeruginosa was most common isolated bacteria in sputum. The detection rate of MDR bacteria in each sample was 30.8% (sputum), 59.2% (urine), 61.8% (others) and 66.7% (blood), correlatively.

Drug Resistance Rate of MDR Bacteria

Among the 193 species of bacteria, 110 species were MDR bacteria with Enterobacteriaceae being the dominant MDR bacteria. E. coli (34.5%, n = 38) ranked as the most frequently isolated MDR bacteria with rates of ESBL-producing and carbapenem-resistant isolates of 69.2% and 3.8%, respectively, following by E. faecium (15.5%, n = 17) and Klebsiella pneumoniae (8.2%, n = 9). MDR ESBL-Enterobacteriaceae (ESBL-E) showed high resistant rate to ampicillin (100%), cefazolin (100%), trimethoprim/sulfamethoxazole (SMZ) (97.1%) and ciprofloxacin (95.8%), were quite sensitive to imipenem, amikacin and piperacillin/tazobactam (PIT), with the resistant rate of 0.0%, 15.2% and 15.6%, correlatively. MDR non-fermentative bacteria mainly including Acinetobacter and Pseudomonas accounted for 17.3% of MDR bacteria. They were most resistant to ceftazidime, imipenem and ciprofloxacin. On the other hand, they showed less resistance rate to amikacin (Table 3).
Table 3

Resistance Rate of MDR Gram-Negative Bacteria of KTR (Resistant Number/Test Number/Resistant Rate %)

AntibioticsEnterobacteriaceae (n = 52)ESBL- E (n = 38)Non-Fermentative Bacteria (n = 19)The Other (n = 2)Total (n = 73)
Cefazolin43/48/90.036/36/10010/10/1001/1/100.054/59/91.5
Ceftazidime32/49/65.326/36/76.514/17/82.31/2/50.047/68/69.1
Cefepime20/46/43.517/32/53.112/16/751/2/50.033/64/51.6
Ampicillin44/44/10030/30/10010/10/1000/1/054/55/98.2
Imipenem2/51/4.00/36/0.015/18/83.31/2/50.018/71/25.4
Amikacin6/46/13.05/33/15.24/12/33.31/1/100.011/59/18.6
Gentamicin32/50/64.022/35/62.910/17/58.80/1/042/68/61.8
Ciprofloxacin26/30/86.723/24/95.811/13/84.61/1/100.038/44/86.4
SMZ46/50/9234/35/97.19/10/90.01/2/50.056/62/90.3
PIT10/43/23.35/32/15.612/16/751/2/50.023/61/37.7
Aztreonam26/33/78.824/28/85.710/10/100.0/36/43/83.7

Abbreviations: SMZ, trimethoprim/sulfamethoxazole; PIT, piperacillin/tazobactam; ESBL- E, extended spectrum β-lactamase-producing Enterobacteriaceae.

Resistance Rate of MDR Gram-Negative Bacteria of KTR (Resistant Number/Test Number/Resistant Rate %) Abbreviations: SMZ, trimethoprim/sulfamethoxazole; PIT, piperacillin/tazobactam; ESBL- E, extended spectrum β-lactamase-producing Enterobacteriaceae. MDR gram-positive bacteria showed high susceptibility to linezolid (100%), followed by vancomycin (97.1%) and rifampicin (68.4%). The tested species showed low susceptibility to ciprofloxacin, gentamicin, clindamycin and carbapenem (< 30%). Less than 9% of the MDR gram-positive bacteria were susceptible to erythromycin and ampicillin. For MDR Enterococcus, they were highly resistant to penicillin, ciprofloxacin and high level of gentamicin, while quite sensitive to linezolid and vancomycin. Among Staphylococcus, 85.7% were resistant to erythromycin and 86.7% were resistant to oxacillin which means they were almost resistant to all β-lactam antibiotics. They were certainly susceptible to linezolid, vancomycin and rifampicin (Table 4).
Table 4

Resistance Rate of Gram-Positive MDR Bacteria for KT Patients (Resistant Number/Test Number/ Resistant Rate [%])

AntibioticsEnterococcus (n = 21)Staphylococcus (n = 16)Total (n = 37)
Ampicillin20/21/95.22/3/66.722/24/91.7
Ciprofloxacin18/19/94.75/10/50.023/29/79.3
Gentamicin18/19/94.79/15/60.027/34/79.4
Streptomycin11/15/73.3/11/15/73.3
Linezolid0/19/00/15/00/34/0.0
Vancomycin1/19/5.30/15/01/34/2.9
Tetracycline6/11/54.53/10/30.09/21/42.9
SMZ/11/16/68.811/16/68.8
Rifampicin5/5/1001/14/7.16/19/31.6
Erythromycin10/10/10012/14/85.722/24/91.7
Clindamycin7/7/10010/16/62.517/23/73.9

Notes: †Enterococcus was tested for sensitivity with high level of gentamicin, while Staphylococcus was tested with gentamicin. ‡Enterococcus was tested for sensitivity with high level of streptomycin, while Staphylococcus was tested with streptomycin.

Abbreviation: SMZ, trimethoprim/sulfamethoxazole.

Resistance Rate of Gram-Positive MDR Bacteria for KT Patients (Resistant Number/Test Number/ Resistant Rate [%]) Notes: †Enterococcus was tested for sensitivity with high level of gentamicin, while Staphylococcus was tested with gentamicin. ‡Enterococcus was tested for sensitivity with high level of streptomycin, while Staphylococcus was tested with streptomycin. Abbreviation: SMZ, trimethoprim/sulfamethoxazole.

The Risk Factors of MDR Bacterial Infection

In order to find out the risk factors, we analyzed the characteristics of MDR bacterial infection group and non-MDR bacterial infection group by univariate and multivariate analysis. Female, age > 46 years old, pathogen types > 1 and postoperative time < 3 months were significant variable in univariate analysis. No significance was demonstrated in age, donor type, and length of hospitalization or clinical characteristics including albumin, creatinine and others. In multivariable analysis, female gender (OR = 3.497, 95% CI = 1.445–8.467, P = 0.006), pathogen types > 1 (OR = 3.832, 95% CI = 1.429–10.273, P = 0.008) and postoperative time < 3 months (OR = 0.331, 95% CI = 0.137–0.799, P = 0.014) were independent risk factors for MDR bacterial infection (Table 5).
Table 5

Univariate and Multivariate Analysis of Risk Factors Associated with the Incidence of MDR Infection

CharacteristicsMDR (n = 80)Non-MDR (n = 50)P -valueOR (95% CI)
Univariate analysis
 Female41110.001*3.727 (1.675–8.295)
 Age > 46 years old33120.047*2.223 (1.012–4.884)
 Diabetes750.8110.863 (0.258–2.853)
 Cadaveric Kidney Donor59290.0871.938 (0.909–4.129)
 Use of FK50663380.7671.140 (0.479–2.412)
 Pathogen types > 12780.030*2.675 (1.102–6.492)
 Postoperative time <3m49280.013*0.363 (0.163–0.808)
 Hospitalization stay > 20d48270.3991.363 (0.664–2.798)
 Infection sites > 1 site1140.3241.883 (0.550–6.109)
 Temperature > 38.5°C29160.6041.221 (0.575–2.593)
 Albumin; < 30 g/l27150.5541.260 (0.586–2.707)
 RDW > 1721140.7300.868 (0.390–1.934)
 Cr > 1.5mg/dl34240.6710.857 (0.419–1.750)
Multivariate analysis
 Female0.006*3.497 (1.445–8.467)
 Pathogen types >10.008*3.832 (1.429–10.273)
 Postoperative time <3m0.014*0.331 (0.137–0.799)
 Age > 46 years old0.8471.094 (0.441–2.716)

Note: *The P-values are statistically significant.

Abbreviations: FK506, tacrolimus; RDW, red blood cell distribution width; Cr, creatinine.

Univariate and Multivariate Analysis of Risk Factors Associated with the Incidence of MDR Infection Note: *The P-values are statistically significant. Abbreviations: FK506, tacrolimus; RDW, red blood cell distribution width; Cr, creatinine.

Discussion

Most of the infection occurred within 3 month postoperatively, especially the first month with UTI being the most common infection which is similar to other studies around the world.12,13 Immunosuppressive therapy as well as present catheters, advanced age, delayed graft function, deceased donor and other risk factors contribute to increase the infection rate.6,14–16 Recent researches also revealed that gut uropathogens abundance could be a risk factor for UTI.17 P. aeruginosa and E. coli were the most frequent isolated bacteria in UTI within the 1st operative 3 months and after the 1 year postoperatively, respectively. However, Alangaden et al found that Enterococcus species were the most common uropathogens during the first month post-transplant, and E. coli was isolated mostly after 6 months.9 It is critical to figure out the microbiological diagnostics of these infections, as it determines the targeted treatment and reduces the excessive use of antimicrobial agents.18 Prevention and proper management of UTI in kidney recipients is essential to reduce the risk of more serious complications, including gram-negative BSI and invasive fungal infection, which associated with reduced allograft survival and all-cause mortality.2,19 Data related to BSI among KTR are limited, BSI with the incidence rate of 3.9–7.3% can lead to reduced allograft and mortality.2,20 However compared with non-transplant patients, transplantation recipients presented decreased mortality since immunosuppressive therapy in transplantation may provide a survival advantage to transplant recipients with sepsis through modulation of the inflammatory response.21 According to recent studies, UTI was most common source of BSI among KTR, while in other transplant recipients central venous catheters were most common source.20,22 Interestingly, results were quite different in our study which indicated that nearly all of BSI came without identified source. This can be explained by the reason that specimens were collected after antibiotic application and other cultures was not performed since the recipients did not have classical symptoms due to immunosuppressed state. Prevention and management of other site infection, in particular UTI, can be a key point in BSI reduction. In the present study, ESBL-E infection accounted for 23.2% of infections. A meta-analysis yielded regional variations that the proportion of KTR affected by an ESBL-E UTI was 2% in North America, 5% in Europe, 17% in South America, and 33% in Asia.10 Compared with non-KTR, KTR are more prone to suffer from infections caused by ESBL-producing strains.23 Age, acute rejection, higher level of immunosuppressant and antibiotics use are found to be associated with the incidence of ESBL-E infection.3,24 Besides that, gastrointestinal colonization with ESBL-E is also an independent risk factor for infection, especially UTI.25 O25 serotype was exhibited high prevalence among KTR around 28.6%, while it was less than 2% in non-immuosuppressed patients. Moreover, the O25 serotype was associated with ESBL-production and quinolone resistance.26–28 ESBL-E infections are accompanied by resistance to a broad range of antibiotics such as β-lactam and carbapenem that are drugs of choice in the treatment of ESBL-E infection. However with the increased usage of carbapenem, it might be partly associated with the spread of carbapenem resistance.29 Carbapenem-sparing regimens mainly including classic and newer β-lactam/β-lactamase inhibitor (BL/BLI) have been proposed to reduce the carbapenem administration, although the mortality and efficacy remained controversial. Several large-scale studies conducted in general population have illustrated that BL/BLI appeared to be as effective as carbapenem both in definitive and empirical therapies of ESBL-E BSI, as well as BL/BLI were associated with fewer MDR and fungal infection.30–32 On the contrast, Tamma et al showed that PIT appeared inferior to carbapenem for the treatment of ESBL bacteremia since there was higher mortality rate among empirical PIT group.33 Currently, the studies focused on kidney transplant setting are limited. According to a study, high effectiveness of PIT, carbapenem and amikacin were reported in KTR. What’s more, it also revealed that ESBL-E isolated from KTR harbored higher resistance genes such as blaCTX-M and blaTEM.23 Two meta-analysis including organ transplant recipients demonstrated that BL/BLI may provide an appropriate and alternative treatment option at some settings.34,35 Recent a multinational retrospective study based on ESBL-E BSI secondary to UTI conducted in KTR has reinforced the efficacy of PIT in ESBL-E infection treatment.36 Besides that, faecal microbiota transplantation has been reported to treat different sites of infections among KTR including carbapenem-resistant Klebsiella pneumoniae infection and ESBL-Klebsiella pneumoniae, which also indicated that it could shift the microbial composition and increased the diversity and abundance of gut microbiota.37,38 According to our results, antibiotics including PIT and amikacin are quite effective against ESBL-E and can be an alternative for ESBL-E infection, but the nephrotoxicity of amikacin may limits its use. However most of these studies are based only on BSI secondary to UTI or other source of infection, and its effectiveness in other site of infection remains unclear. In our center, rifampicin showed relatively great anti-bacterial effect against MDR Staphylococcus. Rifampicin has been mostly known to treat tuberculosis in combination with other drugs. Besides that, rifampicin as adjunctive therapy has been reported successfully in treating or preventing Staphylococcus infections.39–41 It also exhibits an independent protective effect and more efficiency in treating MRSA infection.40,42 In addition to tuberculosis, there are few researches regarding the role of rifampicin in treating in non-tuberculosis infection in KTR or even organ transplant recipients. More trials are needed to assess its role. Regarding risk factors associated with MDR bacterial infection, female, older age and diabetes mellitus were prevalent independent risk factors associated MDR bacterial infection.1,43,44 In our survey, we proved that female gender was a risk factor for MDR bacterial infection while no relationship has been found either with diabetes mellitus or older age. This may due to the small number of diabetes mellitus recipients and patients over 60 years old rarely receive kidney transplant surgery in China. Moreover, 3 months postoperative period was found to be associated with MDR bacterial infection in our center. Since during this interval, delayed graft function, acute rejection, induction of ATG therapy, high levels of immunosuppressant, prolonged use of urinary catheter contribute to the occurrence of MDR bacterial infection.1,3,43 Another study has pointed out that creatinine above 1.5 mg/d, non-fermentative bacteria and polycystic kidney disease were also contributed to higher rate of MDR bacterial infection and even more extensively drug resistant infection.45 However we failed to demonstrated the relationship between creatinine level and MDR bacterial infection. In addition we found recipients who were diagnosed more than 1 pathogen were susceptible to MDR bacterial infection. This study has several limitations. Firstly, it is a single center retrospective study, which limits the applicability of our findings to other populations with different antimicrobial regimens or microbial prevalence. Secondly, since this retrospective study covers a long period, the antibiotics used for drug sensitivity test was a little bit different between earlier years and recent years, some antibiotics such as cefoperazone-sulbactam were not included in the resistance analysis. Thirdly, for some antibiotics such as polymyxin, tigecycline and daptomycin were seldom used in drug sensitivity test in our center particularly in earlier years, so we could not assess resistance rate.

Conclusions

In conclusion, our study identified that E. coli accounted for the most common pathogens and UTI was the most prevalent infection among KTR. In addition, female gender, pathogen types > 1 and 3 months postoperative period were considered as an independent risk factors for MDR bacterial infection. Since MDR infection is increasing, it may be noteworthy to find alternative antimicrobial regimens against MDR infection. Thus, PIT and amikacin may be an alternative choice of ESBL-E infection. Besides that, rifampicin may be effective in treating MDR Staphylococcus infection. Further study is warranted so that we can better prevent infection and optimize empirical treatment protocols while reducing the incidence of MDR bacterial infection.
  45 in total

1.  Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain.

Authors:  A Moreno; C Cervera; J Gavaldá; M Rovira; R de la Cámara; I Jarque; M Montejo; J de la Torre-Cisneros; J Miguel Cisneros; J Fortún; F López-Medrano; M Gurguí; P Muñoz; A Ramos; J Carratalá
Journal:  Am J Transplant       Date:  2007-09-14       Impact factor: 8.086

Review 2.  Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis.

Authors:  Michail Alevizakos; Dimitrios Nasioudis; Eleftherios Mylonakis
Journal:  Transpl Infect Dis       Date:  2017-10-24       Impact factor: 2.228

3.  Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?

Authors:  Sima L Sharara; Joe Amoah; Zoi D Pana; Patricia J Simner; Sara E Cosgrove; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

Review 4.  Colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in solid organ transplantation: A meta-analysis and review.

Authors:  Michail Alevizakos; Athanasios Kallias; Myrto Eleni Flokas; Eleftherios Mylonakis
Journal:  Transpl Infect Dis       Date:  2017-06-20       Impact factor: 2.228

5.  Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome.

Authors:  S Brakemeier; S I Taxeidi; B Zukunft; D Schmidt; J Gaedeke; M Dürr; S Hansen; K Budde
Journal:  Transplant Proc       Date:  2017-10       Impact factor: 1.066

Review 6.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 7.  Epidemiology and impact of bloodstream infections among kidney transplant recipients: A retrospective single-center experience.

Authors:  Ali M Shendi; Gabriel Wallis; Helena Painter; Mark Harber; Sophie Collier
Journal:  Transpl Infect Dis       Date:  2018-01-19       Impact factor: 2.228

8.  Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.

Authors:  Maroun M Sfeir; Gulce Askin; Paul Christos
Journal:  Int J Antimicrob Agents       Date:  2018-08-03       Impact factor: 5.283

9.  A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention.

Authors:  Jaime Lora-Tamayo; Oscar Murillo; José Antonio Iribarren; Alex Soriano; Mar Sánchez-Somolinos; Josu Miren Baraia-Etxaburu; Alicia Rico; Julián Palomino; Dolors Rodríguez-Pardo; Juan Pablo Horcajada; Natividad Benito; Alberto Bahamonde; Ana Granados; María Dolores del Toro; Javier Cobo; Melchor Riera; Antonio Ramos; Alfredo Jover-Sáenz; Javier Ariza
Journal:  Clin Infect Dis       Date:  2012-08-31       Impact factor: 9.079

10.  Fecal Microbiota Transplantation as an Effective Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection in a Renal Transplant Patient.

Authors:  Junpeng Wang; Xin Li; Xiaoqiang Wu; Zhiwei Wang; Xuan Wu; Shanmei Wang; Gaopeng Jing; Tianzhong Yan
Journal:  Infect Drug Resist       Date:  2021-05-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.